Business
CorMedix Inc. Announces Leadership Updates and Operational Changes
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing
About this update from Cormedix Inc.
[{"type":"text","content":"BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regarding its leadership team and changes regarding its international operations: Joe Todisco, Chief Executive Officer of CorMedix, officially joined the organization on Tuesday May 10th. Liz Hurlburt, EVP of Clinical Operations, has been promoted to an expanded role as EVP of Clinical & Medical Affairs, assuming oversight of Medical Affairs, Drug Safety and Pharmacovigilance, in addition to her existing Clinical Operations responsibilities.Donna Ucci has joined the Company as Senior Vice President and Head of Global Quality, reporting directly to the CEO. Donna joins CorMedix after most recently serving as VP Global Quality Management at Amneal Pharmaceuticals, and with more than 20 years Quality leadership experience in previous roles at Impax, Allergan, and Pfizer.Frank Raffaele has joined the company as VP of Supply Chain, and brings more than 30 years of manufacturing and supply chain experience, most recently with Quotient Sciences and Teva Pharmaceuticals.The Company and Tom Nusbickel, EVP and Chief Commercial Officer, have mutually agreed to part ways.The Company will begin the process of winding down its European operations and will discontinue the distribution of Neutrolin, which is CE marked as a medical device in Europe. The Company intends to focus near-term efforts on securing NDA approval and commercialization of DefenCath in the US market. “I am excited to begin my tenure this week at CorMedix,” said Joe Todisco, CorMedix CEO. “The new hires we announced add significant expertise in quality, manufacturing and supply chain, and join a highly skilled team of professionals who I have had the privilege of getting to know over the past several weeks. I look forward to working closely with the broader CorMedix team as we aim to transition to a commercial organization and bring DefenCath to patients.” About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product De...